Might be of interest to some -
https://www.nice.org.uk/news/articles/major-changes-to-type-2-diabetes-treatment-could-save-thousands-of-lives
People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such as semaglutide, dulaglutide and liraglutide) or tirzepatide.
Newer medicines for specific groups
The guidance also expands access to a group of medicines called GLP-1 receptor agonists (such as semaglutide, dulaglutide and liraglutide) and tirzepatide. Semaglutide will now be recommended for people with type 2 diabetes who also have cardiovascular disease caused by blocked arteries (such as previous heart attacks or strokes). GLP-1 receptor agonists and tirzepatide will be recommended for people who were diagnosed before age 40, or who are living with obesity. Around 810,000 more people could benefit from these medicines.
These medicines help manage blood sugar levels while also protecting the heart and kidneys. While some of these medicines are also prescribed separately for weight loss, the recommendations here focus specifically on treating type 2 diabetes.